Dr Linda Bendall

Leukaemia Cell Biology Group

• Research Interests
• Publications
• Contact Details

Dr. Linda Bendall is a Cancer Institute NSW Fellow at The University of Sydney. She graduated from the University of Sydney's Department of Biochemistry, in 1981, with First Class Honours.

After working at the Garvan Research Institute she took an extended break from research for parental duties. She returned to research in 1989 and in 1992 received an NHMRC scholarship to undertake PhD studies into the effect of the bone marrow microenvironment on leukemia and graduated from the University of Sydney's faculty of Medicine in 1996.

In 1997 she received an NHMRC postdoctoral fellowship, which she undertook in Prof James Wiley's laboratory at Nepean Hospital. During this time she maintained close ties with Westmead Hospital. She now heads her own research group, the Leukemia Cell Biology Group which is focused on understanding the role of the bone marrow microenvironment in regulating normal and malignant hematopoiesis.

Research Interests

Dr Bendall’s research work has focused on the impact of non-hematopoietic cells in the bone marrow on the behaviour of leukaemia cells.

The Leukaemia Cell Biology Group has identified SDF-1 as a key molecule that regulates the interaction of leukemic cells with the bone marrow microenvironment, and the growth and survival of leukemic cells. The laboratory is currently involved in pre-clinical trials of agents that disrupt SDF-1 binding to its receptor CXCR4 as a therapeutic strategy for acute lymphoblastic leukemia. It is also investigating the signalling events that occur within the cell following stimulation with SDF-1 and is currently investigating the impact of inhibiting these signalling pathways.

The Leukemia Cell Biology Group consists of a team of post-doctoral scientists, postgraduate students and research staff. The group is supported by state, national and international peer-reviewed grants as well as funding from industry.

Current projects include:

1. CXCR4 antagonists in acute lymphoblastic leukemia in NOD/SCID mice.
2. Enhancement of the effects of cytotoxic agents by mTOR inhibitors in acute lymphoblastic leukemia.
3. Antagonists of p38 MAPK as therapeutics for acute lymphoblastic leukemia.
4. CXCR4 in ALL cell trafficking and chemo-sensitivity.

Publications

- 2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 -

2009

• Crazzolara R, Cisterne A, Thien M, Hewson J, Bradstock KF, Bendall LJ (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113: 3297-3306. [Abstract]
• Juarez J, Dela Pena A, Baraz R, Thien M, Bradstock KF, Bendall LJ (2009) CXCR4 Mediates the Homing of B Cell Progenitor Acute Lymphoblastic Leukemia Cells to the Bone Marrow via Activation of p38MAPK. Brit. J. Haematology. (accepted 3/2/2009)
• Crazzolara R, Bendall LJ. (2009). Emerging treatments in acute lymphoblastic leukemia. Current Cancer Drug Targets 9(1):19-31. [Abstract]
• Johnson M, Sharma M, Jamieson C, Henderson JM, Mok MTS, Bendall LJ, Henderson BR. (2009) Regulation of β-catenin trafficking to the membrane in living cells. Cellular Signalling. 21(2):339-48. [Abstract]
• Crazzolara R, Bradstock KF, Bendall LJ (2009) RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy 5: 727-728  [Abstract]
• Gaundar SS, Bradstock KF, Bendall LJ (2009) p38(MAPK) inhibitors attenuate cytokine production by bone marrow stromal cells and reduce stroma-mediated proliferation of acute lymphoblastic leukemia cells. Cell Cycle 8: 2975-2983 [Abstract]

2008

• Khan NI, Cisterne A, Devidas M, Shuster J, Hunger SP, Shaw P, Bradstock KF, Bendall LJ. (2008) Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor ALL lacking adverse or favorable genetics. Leukemia and Lymphoma (in press) [Abstract]

2007

• Khan NI, Bradstock KF, Bendall LJ. (2007) Activation of Wnt/β-catenin pathway mediates growth and survival in B cell progenitor acute lymphoblastic leukemia. Brit. J Haematol. 138(3):338-48. IF-4.1 38. [Abstract]
• Juarez J, Baraz R, Gaundar S, Bradstock K, Bendall L. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica. 2007 92:450-9. [Abstract]
• Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ. (2007) CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21(6):1249-57. [Abstract]

2006

• Belov, L, Mulligan, S, Barber, N, Woolfson, A, Scott, M, Stoner, K, Chrisp, J, Sewell, W, Bradstock, K, Bendall, L, Pascovici, D, Thomas, M, Erber, W, Huang, P, Sartor, M, Young, G, Wiley, J, Juneja, S, Wierda, W, Green, A, Keating, M, Christopherson, R. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. British journal of haematology. 2006; 135:184-97 [Abstract]
• Khan, N, Bendall, L. Role of WNT signaling in normal and malignant hematopoiesis. Histology and Histopathology. 2006; 21:761-74 [Abstract]
• Christopherson, R, Stoner, K, Barber, N, Belov, L, Woolfson, A, Scott, M, Bendall, L, Mulligan, S. Classification of AML using a monoclonal antibody microarray. Methods in molecular medicine. 2006; 125:241-51 [Abstract]

2005

• Nilsson, S, Johnston, H, Whitty, G, Williams, B, Webb, R, Denhardt, D, Bertoncello, I, Bendall, L, Simmons, P, Haylock, D. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood. 2005; 106:1232-9 [Abstract]
• Bendall, L. Chemokines and their receptors in disease. Histology and histopathology. 2005; 20:907-26 [Abstract]
• Campana, D, Iwamoto, S, Bendall, L, Bradstock, K. Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors. Blood. 2005. p. 4150. [Abstract]
• Bendall, L, Baraz, R, Juarez, J, Shen, W, Bradstock, K. Defective p38 mitogen-activated protein kinase signaling impairs chemotaxic but not proliferative responses to stromal-derived factor-1alpha in acute lymphoblastic leukemia. Cancer research. 2005; 65:3290-8 [Abstract]
• Sloane, A, Raso, V, Dimitrov, D, Xiao, X, Deo, S, Muljadi, N, Restuccia, D, Turville, S, Kearney, C, Broder, C, Zoellner, H, Cunningham, A, Bendall, L, Lynch, G. Marked structural and functional heterogeneity in CXCR4: separation of HIV-1 and SDF-1alpha responses. Immunology and cell biology. 2005; 83:129-43 [Abstract]
• Bendall, L, Bradstock, K. New therapies targeting chemokine receptors: Can changing the way cells traffic be used to treat human disease? Chemokines, Chemokine Receptors, and Disease. 2005; 55:331-365 [Abstract]

2004

• Bendall, L, Nilsson, S, Khan, N, James, A, Bonnet, C, Lock, R, Papa, R, Bradstock, K, Gottlieb, D. Role of CD44 variant exon 6 in acute lymphoblastic leukaemia: association with altered bone marrow localisation and increased tumour burden. Leukemia : 2004 Jul;18(7):1308-11. [Abstract]
• McGowan, E, Saad, S, Bendall, L, Bradstock, K, Clarke, C. Effect of progesterone receptor a predominance on breast cancer cell migration into bone marrow fibroblasts. Breast cancer research and treatment. 2004; 83:211-20 [Abstract]
• Juarez, J, Bendall, L, Bradstock, K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Current pharmaceutical design. 2004; 10:1245-59 [Abstract]
• Juarez, J, Bendall, L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histology and histopathology. 2004; 19:299-309 [Abstract]

2003

• Levesque, J, Hendy, J, Takamatsu, Y, Simmons, P, Bendall, L. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. Journal Of Clinical Investigation. 2003; 111 (2):187-196
• Zannettino, A, Roubelakis, M, Welldon, K, Jackson, D, Simmons, P, Bendall, L, Henniker, A, Harrison, K, Niutta, S, Bradstock, K, Watt, S. Novel mesenchymal and haematopoietic cell isoforms of the SHP-2 docking receptor, PZR: identification, molecular cloning and effects on cell migration. Biochemical Journal. 2003; 370:537-549
• Bendall, L, James, A, Zannettino, A, Simmons, P, Gottlieb, D, Bradstock, K. A novel CD44 antibody identifies an epitope that is aberrantly expressed on acute lymphoblastic leukaemia cells. Immunology And Cell Biology. 2003; 81:311-319
• Juarez, J, Bradstock, K, Gottlieb, D, Bendall, L. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia. 2003; 17:1294-1300

2002

• Saad, S, Gottlieb, D, Bradstock, K, Overall, C, Bendall, L. Cancer cell-associated fibronectin induces release of matrix metalloproteinase-2 from normal fibroblasts. Cancer Research. 2002; 62:283-289

2001

• McQibban, G, Butler, G, Gong, J, Bendall, L, Power, C, Clark-Lewis, I, Overall, M. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. Journal of Biological Chemistry. 2001; 9:23-32.

2000

• Bendall, L, Bradstock, K, Gottlieb, D. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia. 2000; 14:1239-1246
• Gu, B, Zhang, W, Bendall, L, Chessell, I, Buell, G, Wiley, J. Expression of P2X7 purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X7 receptors. American Journal of Physiology-cell Physiology. 2000; 279:C1189-C1197
• Saad, S, Bendall, L, James, A, Gottlieb, D, Bradstock, K. Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. Breast Cancer Research & Treatment. 2000; 63:105-115

Contact Details

T +61 2 9845 9069
F +61 2 9845 9102
E linda_bendall@mail.wmi.usyd.edu.au